Literature DB >> 25889807

The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate?

Francesco Guerra1, Giovanni Battista Levi Sandri2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25889807     DOI： 10.1016/j.jhep.2015.02.053

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  4 in total

1.  IFN-α facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma.

Authors:  Ze Zhang; Ying Zhu; Da Xu; Tian-En Li; Jian-Hua Li; Zi-Tian Xiao; Mo Chen; Xin Yang; Hu-Liang Jia; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Laparoscopic and robotic approach for hepatocellular carcinoma-state of the art.

Authors:  Giovanni Battista Levi Sandri; Edoardo de Werra; Gianluca Mascianà; Marco Colasanti; Roberto Santoro; Vito D'Andrea; Giuseppe Maria Ettorre
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

3.  Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Authors:  Guangfu Li; Dai Liu; Timothy K Cooper; Eric T Kimchi; Xiaoqiang Qi; Diego M Avella; Ningfei Li; Qing X Yang; Mark Kester; C Bart Rountree; Jussuf T Kaifi; David J Cole; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  J Hepatol       Date:  2016-08-09       Impact factor: 25.083

4.  GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages.

Authors:  Jinhong Chen; Zhifei Lin; Lu Liu; Rui Zhang; Yan Geng; Minghao Fan; Wenwei Zhu; Ming Lu; Lu Lu; Huliang Jia; Jubo Zhang; Lun-Xiu Qin
Journal:  Signal Transduct Target Ther       Date:  2021-11-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.